Halozyme Therapeutics Incorporated News - HALO

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and...

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic...

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook PR Newswire SAN DIEGO...

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform PR Newswire SAN DIEGO...

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire SAN DIEGO...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug...

Halozyme to Participate in Upcoming Investor Conferences

Halozyme to Participate in Upcoming Investor Conferences PR Newswire SAN DIEGO, May 8, 2024 SAN DIEGO, May 8...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

biotechinvestor1 2 hours ago

Another 52 week high. Where is EasyComeEasyGo?

Come back and tell us how you were never a bear on this stock and how you timed your moves perfectly ;)

👍️ 1

stockrafter 6 hours ago

To answer a question from the past, with today's example.......

It took took a little over 3 yrs, 2 mns to go from filing to patent......

https://www.freepatentsonline.com/12037618.html

Publication Date: 07/16/2024
Filing Date: 05/21/2021

Will give 20 years for the specific new claims in the new patent, following the long family of similar patents, which were posted earlier.........

"PH20 polypeptide variants, formulations and uses thereof "

👍️ 2

OncoJock 3 days ago

Thank you for sharing your thoughts and perspectives.

As I reflect on this more, I'm thinking perhaps it has to do with the very high degree of institutional ownership. (See attached.) Apparently people like us, retail shareholders, hold only a tiny minority (0.8%) of outstanding shares. I'm guessing institutions take time to make investment decisions, do not act quickly or try to time the market. But that's just a guess.

Good luck to you.

-- OJ

👍️0

biotechinvestor1 4 days ago

Halo’s fundamentals and valuations are absolutely the envy of most. Its share price will continue to do well for the next several years.

Having said this, I am disappointed that Helen has still not delivered on 2 out of the 3 partnerships she guided for 2023. We are almost 7 months into 2024 and still nothing.

The second thing that is irritating is that they seem to be gearing up for an acquisition sooner than I had hoped for. I say this because of the new job posting for an executive director of M&A on halo’s website.

In my view, they need to get a few more Enhanze partnerships before they buy another company.

👍️ 2

stockrafter 4 days ago

Agree both are interesting and worth skimming thru.......

Not sure where the obesity connection will go, but in these days of over consumption, anytime a drug is connected to "obesity," "an intervention" and "a novel therapeutic strategy," an investor needs to take notice.....

With the consortium connection, one would think there would be more info out there on upcoming HVAI deals by now...........

https://subcutaneousconsortium.org/membership-overview/

👍️ 1

OncoJock 4 days ago

Thank you for sharing your perspective.

👍️0

maumar 5 days ago

I would guess there are several reasons.

First of all, Halo is not a small-cap stock. Several other mid-cap and large biotechs didn’t participate (Asnd, Argx and others.)

Second, Halo is up 55% from six months ago and, for better or worse, is not the type of biotech that can make huge moves up or down overnight. It is a lower risk/lower reward stock than many other biotechs.

Third, the stock peaked around $50, $54 and then $59 in 2021 and 2022. In 2022, Halo sold convertible notes that have a conversion price of $56. Because of all of the above, the stock has a lot of resistance in this area.

👍️ 3

Howeeme 5 days ago

Halo beats to its own drum. Institutions own most of it and traders play with it. Fundamentals are great and that drives the price. It’s going to go much higher sooner than later. Last time it made highs a few years ago the price dropped over 30 percent very quickly. This time it’s holding tight.

👍️ 3

OncoJock 5 days ago

Does anyone have any theories as to why . . .

HALO did not participate in today's strong rally that drove the price of so many small caps upward?

According to the Wall Street Journal, today the Russell 2000 index of small-cap stocks soared 3.6% in its best day since November. Some of my other small biotech stocks (I own half a dozen) jumped 5, 7, even 9%. Every darned holding in my brokerage list (roughly 14) was green EXCEPT for HALO, which was in the red, down slightly.

This defies logic, in my world. The company is becoming a cash cow. We've been held hostage, or so I thought, by the stubbornly high yield on the 10-year Treasury. But even when the 10-year yield dropped sharply today, the HALO price did not budge.

I'd be interested in what other shareholders on this board think might be the reason HALO did not participate in today's strong small-cap rally.

-- OJ

P.S. Even my utilities ETF advanced!

👍️0

biotechinvestor1 5 days ago

Nice finds. Both links are interesting.

👍️0

stockrafter 5 days ago

Shhh, its all a secret…..

Acknowledgement: PEGPH20 is an in-kind gift from Halozyme Therapeutics, Inc under a Material Transfer Agreement.
https://www.biorxiv.org/content/10.1101/2024.06.22.600183v1.full.pdf

This consortium is actually mentioned in the HVAI filing…..
https://subcutaneousconsortium.org/news-and-events/

👍️ 2

maumar 6 days ago

I also don't think it was a sector thing. There was quite a bit of churn yesterday, even today volume was a bit higher than average and Halo was weaker than the sector. It may just be that there is a lot of resistance in this area and the stock is consolidating. Also, I am sure some investors are skeptical that there will be more positive surprises or new deals soon. Time will tell.

biotechinvestor1 6 days ago

Talking about full year 2024 PE.

If we end 2024 at the same PE we ended 2023, we will be in the $70-80 range, simply because the E (earnings) has gone up so much.

Here is the full 2023 and 2024 PE ratios:

https://www.nasdaq.com/market-activity/stocks/halo/price-earnings-peg-ratios

👍️ 1

OncoJock 6 days ago

Not to my knowledge, but it's hard to keep all of our many customers straight. (That's a good problem to have.)

Agree with this perspective, thanks for sharing.

When you talk about P/E, are you thinking trailing 12 months (TTM) or forward 12 months (FY)? As I'm sure you know, these can be very different numbers.

-- oj

👍️0

MysticalGladiator72 6 days ago

If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now

https://finance.yahoo.com/news/invested-1000-halozyme-therapeutics-decade-123003402.html

👍️0

biotechinvestor1 6 days ago

Agreed

👍️0

biotecholdguy 6 days ago

Besides making a profit...Think about the millions of sick people that get to be helped by HALO !!
so awesome.

👍️ 3

biotechinvestor1 6 days ago

Unlikely that it was a sector thing.

1) XBI did not have a reversal in the second half of day like halo did

2) halo’s volume was unusually high

3) halo reached another 52 week high

Who knows what a single day of trading is all about. It’s the trend and fundamentals that matter.

👍️0

Fred Kadiddlehopper 6 days ago

I think it was a sector thing. Had similar moves in other biotech stocks. There was some indication of a likely Fed move to lower interest rates and that usually creates a nice bump in the space. Just a guess, though.

👍️0

bleedpurple 6 days ago

Maybe some big boy shorts closing out and going long w MM help? Halo pretty highly shorted. I’m glad to be long right now.

👍️0

biotechinvestor1 7 days ago

No idea.

👍️0

maumar 7 days ago

What do you make of the stock action today?

👍️0

biotechinvestor1 7 days ago

been in Halozyme since 2011. Back then, I bought once or twice a year as this was a speculative investment (PEGPH20) with the back up plan of Enhanze.

I started buying on a regular basis since they became profitable and the P/E ratio and Peg were/are super attractive.

In my retirement account I purchase halo 3 times a year. In my taxed account I buy on a weekly basis and more on the dips.

I am in a handful of other profitable, high profit margin, reasonable value stocks, but the rest of my portfolio is in index funds.

Valuations and fundamentals are like gravity. Mr. market can only defy them for a limited time. Halozyme is profitable and it’s profits are growing. The share prices will go up overtime no matter what. My strategy is simple. Buy and hold for as long as the PE ratio and the peg are below industry averages, and comps.

I don’t see myself selling until Peg is above 1.2 and PE ratio is above 27. We are far from both.

👍️ 4

maumar 7 days ago

Just curious what your strategy is. Do you add just a few shares at a time? What is your average cost per share in your position?

👍️0

biotechinvestor1 1 week ago

loving the dips. Thank you, Mr. Market for the opportunity to accumulate.

👍️0

Fred Kadiddlehopper 1 week ago

That was my impression, Howee. I was wondering why the other poster was asking about it.

👍️0

Howeeme 1 week ago

It does not and neither does methotrexate. Just commenting on the AI and the experience for the patient.

👍️0

Fred Kadiddlehopper 1 week ago

Are you contending that subcu Dupixent contains hyaluronidase?

👍️0

Roger1 1 week ago

Thank you for this. Perhaps Dupixent should be looking at us for their AI. That should be an easy sell for HALO.

👍️0

Howeeme 1 week ago

Don’t really know the biology of Dupixent but I have family that uses Dupixent and Methtrexate both using Auto Injectors. Halozyme produces the Methtrexate AI and it goes very smoothly. The Dupixent AI is very painful and hard to handle.

👍️ 2

Roger1 1 week ago

Wonder where Sanofi got the molecule for subq Dupixent used in copd trials. Any thoughts?

👍️0

Roger1 1 week ago

Are we supplying Hylenex for Dupixent? Memory slipping...

👍️0

OncoJock 1 week ago

This looks very interesting: 3 Halozyme employees rubbing shoulders in a professional context for half a day with employees from Roche, Sanofi, Lilly, Merck, AZ, and Novartis. Roche is already a repeat customer of Halozyme's, while Sanofi, Lilly, Merck, AZ and Novartis are all prospective customers. With no sign of any Halozyme competitors present among the presenters. How can this not be a wonderful thing for Halozyme???

👍️ 1

stockrafter 1 week ago

https://2024crsannualmeeting.eventscribe.net/agenda.asp?pfp=days&day=7/8/2024&theday=Monday&h=Monday%20July%208&BCFO=P%7CG

Hoping for some deals for the effort.......

👍️ 2

halofan 1 week ago

Ok, thanks for the explanation. HALO, unlike those other companies, has earned the right to be the darling of social media!!

👍️0

biotechinvestor1 1 week ago

It was a joke. Roaring Kitty is the guy behind the runs in Gamestop, AMC, and other meme stocks.

Most of these “meme stocks” had large short interests. The shorts were squeezed (by masses of social media retail investors) and share price ran up.

Most meme stocks were not fundamentally sound businesses which is why their run up did not last long

Halo has the potential for a short squeeze and the beautiful fundamentals for long term performance.

👍️ 1

halofan 1 week ago

Sorry, but I don’t understand your comment.

👍️0

Fred Kadiddlehopper 1 week ago

HALO a meme stock. That's funny!

👍️0

biotechinvestor1 2 weeks ago

Let Roaring Kitty know :)

👍️ 1

halofan 2 weeks ago

I just noticed that the most currently reported short interest was up substantially. I guess that might be why the stock has struggled despite all the good news. But I can’t understand why there would be so much short selling when there has been nothing but good news. They might find out soon that that was not such a good move.

👍️ 1

OncoJock 2 weeks ago

Great story. Thanks for sharing!

P.S. It seems like business journalists are finally starting to understand the new HALO business model:

Halozyme's business model is relatively simple. The company licenses its technology to Big Pharma and biotech companies and they use it to develop subcutaneous versions of their biggest IV drugs. In return, Halozyme receives a royalty on sales of those products.

👍️0

biotechinvestor1 2 weeks ago

50 ml subcutaneous is notable

👍️0

stockrafter 2 weeks ago

Good highlights....it is an informative patent filing......need to read the attached documents as well....

Some additional info on Takeda.......hard to imagine they will not be using a HALO HVAI eventually...........

https://link.springer.com/article/10.1007/s10875-024-01742-5

Tolerability and Safety of Large-Volume Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% Administered with or without Dose Ramp-Up: A Phase 1 Study in Healthy Participants

Published: 19 June 2024

👍️ 2

biotechinvestor1 2 weeks ago

https://www.investors.com/research/the-new-america/halozyme-enhanze-platform-roche-tecentriq-argenx-vyvgart-johnson-johnson-darzalex/

👍️ 3

biotechinvestor1 2 weeks ago

From the recent patent filling:

Interesting.... $HALO @halozymeinc pic.twitter.com/pZwqLNBOyM— Emmanuele (@Biotech2050) July 1, 2024

👍️ 1

stockrafter 2 weeks ago

https://ascpt.onlinelibrary.wiley.com/doi/10.1111/cts.13788

Good article, wonder why HALO doesn't post it on their site.... been waiting.... so posting it here.....

"SC administration with rHuPH20 yielded a 30% increase in absorption rate on average and similar or better bioavailability. "

👍️ 2

biotechinvestor1 2 weeks ago

All dips are to be bought. Fundamentals drive share performance over time. New highs are inevitable.

👍️ 1

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Halozyme Therapeutics Incorporated (HALO)

Empower your portfolio: Real-time discussions and actionable trading ideas.

HALO News

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

Halozyme to Participate in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

HALO Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Halozyme Therapeutics Incorporated (HALO) News

Halozyme Therapeutics Incorporated (HALO)

Empower your portfolio: Real-time discussions and actionable trading ideas.

HALO News

Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook

Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform

Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

Halozyme to Participate in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

HALO Discussion

Your Recent History

Company

Business

Popular

Get The App